Literature DB >> 7692360

RP 67580, a selective antagonist of neurokinin-1 receptors, modifies some of the naloxone-precipitated morphine withdrawal signs in rats.

R Maldonado1, D Girdlestone, B P Roques.   

Abstract

In order to clarify the participation of substance P in the expression of opiate withdrawal, we have investigated the effects induced by the new selective neurokinin-1 antagonist RP 67580 on naloxone-induced morphine withdrawal syndrome in rats. Intracerebroventricular administration of RP 67580 elicited a decrease in 7 of the 13 withdrawal signs evaluated. Mastication, salivation and signs related to the motor component of withdrawal (jumping, rearing and locomotor activity) were particularly reduced. One sign, wet dog shakes, was increased, but it was also enhanced by the inactive enantiomer RP 68651. Our results indicate that blockade of NK1 receptors induces a decrease in the expression of naloxone-precipitated morphine abstinence in rats, and support the participation of substance P in the opiate withdrawal response.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7692360     DOI: 10.1016/0304-3940(93)90457-v

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  11 in total

1.  Effects of the NK1 antagonist, aprepitant, on response to oral and intranasal oxycodone in prescription opioid abusers.

Authors:  Sharon L Walsh; Markus Heilig; Paul A Nuzzo; Pam Henderson; Michelle R Lofwall
Journal:  Addict Biol       Date:  2012-01-19       Impact factor: 4.280

2.  Increased morphine analgesia and reduced side effects in mice lacking the tac1 gene.

Authors:  A Bilkei-Gorzo; J Berner; J Zimmermann; R Wickström; I Racz; A Zimmer
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

Review 3.  Neurobiology of addiction: a neurocircuitry analysis.

Authors:  George F Koob; Nora D Volkow
Journal:  Lancet Psychiatry       Date:  2016-08       Impact factor: 27.083

4.  Discovery of Novel Multifunctional Ligands with μ/δ Opioid Agonist/Neurokinin-1 (NK1) Antagonist Activities for the Treatment of Pain.

Authors:  Aswini Kumar Giri; Christopher R Apostol; Yue Wang; Brittany L Forte; Tally M Largent-Milnes; Peg Davis; David Rankin; Gabriella Molnar; Keith M Olson; Frank Porreca; Todd W Vanderah; Victor J Hruby
Journal:  J Med Chem       Date:  2015-10-30       Impact factor: 7.446

5.  The role of spinal neuropeptides and prostaglandins in opioid physical dependence.

Authors:  Tuan Trang; Maaja Sutak; Remi Quirion; Khem Jhamandas
Journal:  Br J Pharmacol       Date:  2002-05       Impact factor: 8.739

6.  An in vitro model of morphine withdrawal manifests the enhancing effect on human immunodeficiency virus infection of human T lymphocytes through the induction of substance P.

Authors:  Xu Wang; Steven D Douglas; Jin-Song Peng; Dun-Jin Zhou; Qi Wan; Wen-Zhe Ho
Journal:  Am J Pathol       Date:  2006-11       Impact factor: 4.307

7.  Opioid-like effects of the neurokinin 1 antagonist aprepitant in patients maintained on and briefly withdrawn from methadone.

Authors:  Jermaine D Jones; Taylor Speer; Sandra D Comer; Stephen Ross; John Rotrosen; Malcolm S Reid
Journal:  Am J Drug Alcohol Abuse       Date:  2013-03       Impact factor: 3.829

Review 8.  Bi- or multifunctional opioid peptide drugs.

Authors:  Peter W Schiller
Journal:  Life Sci       Date:  2009-03-11       Impact factor: 5.037

9.  Expression of mu opioid receptor in dorsal diencephalic conduction system: new insights for the medial habenula.

Authors:  O Gardon; L Faget; P Chu Sin Chung; A Matifas; D Massotte; B L Kieffer
Journal:  Neuroscience       Date:  2014-07-31       Impact factor: 3.590

10.  Building a better analgesic: multifunctional compounds that address injury-induced pathology to enhance analgesic efficacy while eliminating unwanted side effects.

Authors:  T M Largent-Milnes; S W Brookshire; D P Skinner; K E Hanlon; D Giuvelis; T Yamamoto; P Davis; C R Campos; P Nair; S Deekonda; E J Bilsky; F Porreca; V J Hruby; T W Vanderah
Journal:  J Pharmacol Exp Ther       Date:  2013-07-16       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.